IRLAB Therapeutics 收到了 FDA 对第二阶段的积极反馈，计划进行帕金森病治疗美多培坦的第三阶段。 IRLAB Therapeutics receives positive FDA feedback for Phase 2, planning Phase III for Parkinson's treatment mesdopetam.
帕金森病治疗开发商 IRLAB Therapeutics 已收到最近与美国 FDA 举行的第二阶段结束会议的书面记录。 IRLAB Therapeutics, a Parkinson's disease treatment developer, has received written minutes from a recent End-of-Phase 2 meeting with the US FDA. 会议纪要证实了之前分享的积极口头反馈。 The minutes confirmed the positive verbal feedback shared earlier. 基于这一成功成果，IRLAB 计划在 FDA 对其开发计划进行评估后，继续推进美多哌坦 III 期项目的准备工作。 Based on this successful outcome, IRLAB plans to move forward with the preparations for a Phase III program for mesdopetam, following the evaluation of its development plan by the FDA.